CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Revenues:
Clinical laboratory services	$ 19,530	$ 18,837	$ 39,864	$ 37,395
Product revenues	7,122	6,983	14,203	14,409
Royalty and license fee income	300	440	561	740
Total revenues	26,952	26,260	54,628	52,544
Operating costs and expenses:
Cost of clinical laboratory services	11,730	11,052	23,772	21,948
Cost of product revenues	3,877	3,520	7,266	6,829
Research and development	812	483	1,559	1,305
Selling, general and administrative	11,070	11,218	21,961	22,712
Provision for uncollectible accounts receivable	779	679	1,593	1,348
Legal fee expense	1,700	370	2,131	742
Total operating costs and expenses	29,968	27,322	58,282	54,811
Operating loss	(3,016)	(1,062)	(3,654)	(2,340)
Other income (expense):
Interest	185	79	342	125
Other	33	24	69	143
Foreign exchange gain (loss)	800	(94)	605	(455)
Loss before income taxes	(1,998)	(1,053)	(2,638)	(2,527)
Benefit for income taxes	1,097	0	1,097	0
Net loss	$ (901)	$ (1,053)	$ (1,541)	$ (2,527)
Net loss per common share:
Basic and diluted (in Dollars per share)	$ (0.02)	$ (0.02)	$ (0.03)	$ (0.05)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	46,941	46,292	46,806	46,282